CORONAVIRUS

AstraZeneca wades deeper into COVID therapeutics

The experimental antibody therapies are designed to target people with compromised immune systems.

In Summary

•The experimental antibody therapies are designed to target people with compromised immune systems.

•AstraZeneca signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies.

A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021.
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021.
Image: REUTERS

AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical giant said on Tuesday.

The experimental antibody therapies - developed by RK Bio, include those designed to target people with compromised immune systems - such as AstraZeneca's own antibody cocktail, Evusheld, which is already approved in multiple countries.

“WATCH: The latest videos from the Star”